1. Scrip
  2. >>Business

BI Gets Down To Business Early With Trio Of Pacts

 
• By Kevin Grogan

The German group’s fibro-inflammatory deal with Kyowa Kirin has come in the same week as a new oncology collaboration with partner 3T and a liver disease alliance with China’s Ribo.

Boehringer Ingelheim headquarters in Ingelheim, Germany
• Source: Boehringer Ingelheim (dieth+schröder-fotografie)

The J.P. Morgan Healthcare Conference in San Francisco has yet to kick off but Boehringer Ingelheim GmbH has already inked three deals this January, the latest being a link-up with Kyowa Kirin Co., Ltd. in the fibrosis space.

The companies have entered into a license agreement which will see BI receive exclusive, worldwide rights from Kyowa Kirin to develop a novel, first-in-class treatment for fibro-inflammatory diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.